MLAB Stock Cash Flow Statements

Mesa Laboratories Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Mesa Laboratories Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2014-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30

cash flows from operating activities:
net income	4,742,000	-7,114,000	-1,676,000	3,428,000	3,388,000	-254,583,000				611,000	451,000	1,306,000	-1,438,000	-1,784,000	-2,060,000	3,720,000	1,995,000	3,920,000	-4,542,000	2,871,000	1,025,000	-1,680,000	-4,630,000	3,062,000	4,597,000	1,402,000	858,000	994,000	4,230,000	4,254,000	-11,086,000	2,358,000	1,930,000	4,750,000	2,361,000	3,552,000	1,932,000	1,860,000	2,559,000	1,543,000	2,249,000	2,099,000	2,199,000	1,987,000	2,054,000	1,679,000	2,177,000	1,257,000	1,429,000	1,320,000	1,345,000	1,155,000	1,243,000	1,026,000	1,204,000	1,216,000	1,354,000	1,016,000
adjustments to reconcile net income to net cash from operating activities:
depreciation of property, plant and equipment	1,404,000	1,354,000	1,106,000	1,518,000	1,404,000	1,334,000
amortization of intangible assets	4,553,000
stock-based compensation expense	3,881,000	3,138,000	3,239,000	3,837,000	2,928,000	2,792,000	2,993,000	3,183,000	2,968,000		2,056,000	4,371,000	3,432,000		3,703,000
gain on extinguishment of convertible notes			310,000	0	-3,197,000
amortization of step-up in inventory basis		0	0	454,000	778,000									1,400,000				0	0	0	-436,000	3,368,000
foreign currency adjustments	-5,986,000																												-123,000	-235,000	278,000	-95,000	67,000	-32,000	-562,000
other	1,250,000	1,032,000	5,014,000	-2,509,000	1,409,000	2,243,000	-2,751,000	854,000	283,000	749,000	277,000	1,127,000	-1,763,000	-601,000	291,000	602,000	-826,000	1,446,000	-1,784,000	415,000	84,000	-179,000	73,000	119,000	64,000	-90,000	24,000
cash from changes in operating assets and liabilities:
accounts receivable	3,436,000	-3,016,000	657,000	-4,048,000	3,482,000	-3,354,000	2,846,000	-1,008,000	6,456,000	-142,000	678,000	-1,173,000	-1,484,000	-4,494,000	-3,323,000	-2,220,000	3,285,000	-2,871,000	-853,000	-1,174,000	4,251,000	-1,676,000	-235,000	833,000	-587,000	699,000	250,000	-1,187,000	1,830,000	-1,941,000	489,000	-990,000	2,890,000	-2,030,000	-596,000	-3,377,000	-716,000	2,099,000					-421,000
inventories	-3,290,000	1,692,000	-495,000	627,000	-671,000	2,346,000	401,000	1,060,000	-1,244,000	-991,000	-5,126,000	-1,333,000	-2,732,000	-1,396,000	1,159,000	-55,000	-753,000	1,414,000	-21,000	730,000	-1,194,000	-191,000	310,000	209,000	86,000	1,272,000	280,000	493,000	529,000	872,000	454,000	-281,000	-67,000	699,000	-1,353,000								419,000
prepaid expenses and other assets	-2,436,000		4,000	-2,418,000	969,000	8,052,000	-4,313,000	-1,080,000	-2,448,000	1,802,000	740,000	-872,000	-2,180,000	-1,673,000	-460,000	158,000	-1,631,000	5,569,000	-750,000	41,000	-1,982,000	1,978,000
accounts payable	212,000	1,531,000	-1,730,000	199,000	-388,000	1,559,000	-349,000	-768,000	-539,000	-206,000	-1,582,000	448,000	-205,000	100,000	1,437,000	309,000	-476,000	896,000	1,675,000	-691,000	-913,000	-125,000	635,000	-621,000	50,000	781,000	381,000	-564,000	494,000	351,000	-7,000	727,000	-66,000	-230,000	15,000	413,000	-277,000	611,000	127,000	207,000	-309,000	412,000
accrued liabilities and taxes payable	-5,928,000		4,667,000	23,000	-2,811,000	-1,112,000	1,619,000	1,474,000	-3,217,000		648,000	-541,000	-5,328,000	1,658,000	3,193,000	-5,463,000	867,000	2,200,000	2,294,000	-434,000	-4,377,000	2,249,000	989,000	-1,113,000	-4,272,000	2,102,000	4,241,000	660,000	-1,526,000	2,159,000	68,000	-1,808,000	-3,584,000	2,155,000	-2,075,000
unearned revenues	55,000	-89,000	460,000	-390,000	-919,000	1,070,000	-307,000	-1,036,000	-135,000	-312,000	540,000	-1,058,000	1,436,000	1,530,000	73,000	845,000	138,000	919,000	663,000	1,159,000	-1,299,000	527,000	213,000	-105,000	119,000	233,000	-2,000	-86,000	-91,000	246,000	-130,000	-79,000	40,000	217,000	-232,000
net cash from operating activities	1,893,000	12,665,000	18,439,000	5,271,000	10,433,000	12,883,000	11,535,000	9,776,000	9,939,000	12,519,000	7,718,000	10,557,000	-2,811,000	9,302,000	15,898,000	4,434,000	9,589,000	13,520,000	10,943,000	10,542,000	2,068,000	8,403,000	11,018,000	6,414,000	724,000	10,262,000	10,092,000	3,657,000	6,543,000	9,641,000	7,805,000	-2,303,000	3,632,000	6,950,000	991,000										1,687,000	2,888,000	1,842,000	2,957,000	1,488,000	2,586,000
capex	-1,009,000	-757,000	-813,000	-1,788,000	-891,000	-535,000	-1,128,000	-634,000	-270,000	-1,026,000	-1,654,000	-1,639,000	-225,000	-782,000	-2,059,000	-938,000	-653,000	-1,038,000	-247,000	-491,000	-216,000	-563,000	-392,000	-317,000	-226,000	-55,000	-358,000	-549,000	-300,000	-259,000	-528,000	-3,213,000	-3,456,000	-1,438,000	-1,256,000										0	0	0	0	0	0
free cash flows	884,000	11,908,000	17,626,000	3,483,000	9,542,000	12,348,000	10,407,000	9,142,000	9,669,000	11,493,000	6,064,000	8,918,000	-3,036,000	8,520,000	13,839,000	3,496,000	8,936,000	12,482,000	10,696,000	10,051,000	1,852,000	7,840,000	10,626,000	6,097,000	498,000	10,207,000	9,734,000	3,108,000	6,243,000	9,382,000	7,277,000	-5,516,000	176,000	5,512,000	-265,000										1,687,000	2,888,000	1,842,000	2,957,000	1,488,000	2,586,000
cash flows from investing activities:
purchases of property, plant and equipment	-1,009,000	-757,000	-813,000	-1,788,000	-891,000	-535,000	-1,128,000	-634,000	-270,000	-1,026,000	-1,654,000	-1,639,000	-225,000	-782,000	-2,059,000	-938,000	-653,000	-1,038,000	-247,000	-491,000	-216,000	-563,000	-392,000	-317,000	-226,000	-55,000	-358,000	-549,000	-300,000	-259,000	-528,000	-3,213,000	-3,456,000	-1,438,000	-1,256,000
net cash (used in) investing activities	-1,009,000	-1,007,000	-813,000	-1,788,000	-891,000	426,000	-80,828,000	-634,000	-270,000	-1,026,000	-6,604,000	-1,639,000	-225,000	-782,000	-302,852,000	-938,000	-653,000	-1,038,000	-247,000	-491,000	-216,000	-548,000
cash flows from financing activities:
proceeds from debt borrowings	10,500,000
debt repayments	-7,438,000
gke acquisition-related holdback payment	-9,555,000
repurchase of convertible notes
dividends paid	-873,000	-870,000	-869,000	-866,000	-863,000	-864,000
other financing	-1,061,000	858,000	20,000	-307,000	-1,023,000	-567,000
net cash (used in) financing activities	-8,427,000			-8,610,000	-9,109,000			-5,560,000	-9,519,000
effect of exchange rate changes on cash and cash equivalents	1,501,000	900,000	-410,000	992,000	-175,000	-386,000	1,052,000	-341,000	-684,000	-292,000	1,493,000	-1,642,000	-1,156,000	-833,000	-834,000	-2,070,000	2,644,000	-1,301,000	940,000	703,000	834,000	-848,000	-175,000	-135,000	102,000	-136,000	-33,000	-247,000	130,000	237,000	-257,000	14,000	4,000	29,000	-35,000
net increase in cash and cash equivalents	-6,042,000		6,619,000	-4,135,000	258,000							-11,370,000	-5,599,000	-2,360,000	-226,588,000	2,584,000	11,845,000	10,134,000	11,807,000	10,973,000	149,571,000	7,401,000	-171,464,000	238,128,000	-2,870,000	4,456,000	104,000	-1,775,000	1,931,000	-374,000	-4,425,000			2,423,000	-2,188,000								1,500,000	739,000	-1,102,000	2,508,000					531,000	-1,293,000	474,000	1,648,000	1,149,000	1,234,000	338,000	620,000
cash and cash equivalents at beginning of period	27,321,000	0	0	0	28,214,000	0	0	0	32,910,000	0	0	0	49,346,000	0	0	0	263,865,000	0	0	0	81,380,000		0	0	10,185,000				5,469,000		0	0	5,695,000		0	1,569,000	0	4,006,000		0	0	7,191,000		0	0	3,546,000		0	0	10,471,000		0	0	9,111,000		0	0	5,770,000
cash and cash equivalents at end of period	21,279,000	-3,635,000	6,619,000	-4,135,000	28,472,000	-10,000	-7,393,000	3,241,000	32,376,000	6,809,000	-6,276,000	-11,370,000	43,747,000	-2,360,000	-226,588,000	2,584,000	275,710,000	10,134,000	11,807,000	10,973,000	230,951,000		-171,464,000	238,128,000	7,315,000				7,400,000		-4,425,000	433,000	4,637,000		-2,188,000	-1,997,000	-165,000	3,589,000		-50,000	-1,821,000	4,593,000		739,000	-1,102,000	6,054,000		-1,446,000	1,034,000	2,541,000		-1,293,000	474,000	10,759,000		1,234,000	338,000	6,390,000
amortization of acquisition-related intangibles		6,143,000	4,391,000	4,550,000	4,061,000	4,961,000
gain on extinguishment of convertible senior notes
non-cash interest expense and debt issuance cost amortization
deferred taxes												0	-908,000								360,000								-93,000
impairment loss on goodwill and finite-lived intangible assets
prepaid expenses and other assets, pending taxes
accrued liabilities and taxes payable, pending taxes
acquisition of customer lists
acquisition of businesses, net of cash acquired and holdback liabilities
proceeds from credit facility borrowings
repayment of debt		-17,938,000	-9,438,000	-7,437,000	-9,438,000	-11,500,000
repurchase of convertible senior notes
proceeds from the exercise of stock options						0	2,000	304,000	52,000	2,474,000	881,000	2,206,000	1,436,000	1,800,000	2,271,000	1,992,000	1,089,000	734,000	991,000	1,047,000	1,654,000	1,097,000	341,000	798,000	2,709,000	1,507,000	412,000	133,000	3,043,000	573,000	282,000	607,000	1,160,000	123,000	954,000	500,000	455,000	182,000	100,000	181,000
payment of tax withholding obligation on vesting of restricted stock						-2,000	-12,000	-2,000	-712,000	-10,000
net cash from financing activities		-16,193,000				-12,933,000				-4,392,000	-8,883,000	-18,646,000	-1,407,000	-10,047,000	61,200,000	1,158,000	265,000	-1,047,000	171,000	219,000	146,885,000	394,000	-368,000	232,166,000	-915,000	-5,615,000	-4,757,000	-6,858,000	-4,442,000	-9,908,000	3,926,000	6,771,000	1,327,000	-2,206,000	624,000				-1,415,000	-3,289,000	-3,150,000	10,835,000
net (decrease) in cash and cash equivalents						-10,000			-534,000
acquisitions, net of cash acquired										0				0
proceeds from the issuance of debt			0	0	73,465,000	0								0												0				0	7,000,000	8,000,000	1,500,000	0	2,500,000				0	0
repurchase of convertible debt			-310,000	0	-71,250,000
non-cash interest and debt amortization						234,000	231,000	231,000	230,000			227,000	225,000	225,000	361,000	222,000	221,000	1,373,000	1,357,000	1,341,000	1,326,000	1,312,000
acquisitions, net of cash acquired and holdback liabilities
net								-1,230,000	-549,000
depreciation and amortization								8,096,000	8,134,000	9,055,000	8,580,000	8,055,000	8,134,000	9,382,000	6,837,000	4,277,000	4,572,000	4,727,000	4,600,000	4,425,000	3,908,000	5,489,000	3,057,000	2,263,000	2,181,000	2,266,000	2,273,000	2,434,000	2,455,000	2,490,000	2,450,000	2,241,000	2,170,000	1,967,000	1,768,000	2,523,000	828,000	811,000	847,000	910,000	891,000	784,000	579,000	534,000	561,000	541,000	545,000	465,000	417,000	417,000	249,000	176,000	175,000	186,000	207,000	200,000	190,000	191,000
cash from changes in operating assets and liabilities:
payments of debt								-5,000,000	-8,000,000	-6,000,000	-8,000,000	-20,000,000	-2,000,000	-11,000,000								0
dividends								-862,000	-859,000	-856,000	-855,000	-852,000	-843,000	-844,000	-837,000	-834,000	-824,000	-824,000	-819,000	-818,000	-704,000	-703,000	-698,000	-697,000	-624,000	-619,000	-617,000	-616,000	-610,000	-606,000	-606,000	-586,000	-583,000	-579,000	-580,000
adjustments to reconcile net income to net cash from operating (used in) activities:
stock-based compensation																	2,197,000	2,381,000	3,611,000	2,008,000	1,268,000	215,000	3,260,000	1,182,000	868,000	1,788,000	695,000	990,000	739,000	249,000	438,000	412,000	429,000	326,000	344,000	419,000	208,000	149,000
changes in operating assets and liabilities:
other accrued expenses
proceeds from the issuance of common stock																		0	0	0	145,935,000	0	0
payments of contingent consideration														-3,000				-293,000	-1,000			0
payment of debt issuance costs
proceeds from the sale of assets
proceeds from the issuance of convertible senior notes																						5,430,000	0
impairment loss on goodwill and long-lived assets																						0				1,105,000
cash from changes in operating assets and liabilities
acquisitions																						0	-181,547,000	0	-2,555,000	0				-85,000	-15,371,000	-836,000	-2,565,000	-912,000	-2,512,000
change in inventory reserve																			110,000	211,000	47,000	-937,000	507,000	-127,000	197,000	-429,000			67,000	354,000
gain on disposition of assets																										0	0				0
adjustment to contingent consideration																						-10,000	2,000			0	1,000	159,000	-192,000	0	0
proceeds from sale of assets																										0	0			0	0
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
supplemental non-cash activity:
deferred tax liability related to the conversion option associated with the convertible senior notes																						-1,089,000	0
contingent consideration as part of an acquisition																									513,000							654,000	1,168,000	-270,000	0
cash paid for:
income taxes paid																										236,000	324,000
interest paid																										344,000	355,000
non-cash interest and other
cash used by changes in operating assets and liabilities
prepaid expenses and other																								71,000	-2,579,000				-1,340,000	2,442,000	554,000	-83,000	-426,000	351,000	649,000					-20,000	29,000	105,000
contingent consideration																										-3,000	6,000	-220,000	-463,000	0	-449,000	-4,705,000	111,000	-288,000	431,000
net cash from investing activities																								-317,000	-2,781,000	-55,000	-5,198,000	1,673,000	-300,000	-344,000	-15,899,000	-4,049,000	-6,021,000	-2,350,000	-3,768,000
payments on debt																								-20,000,000	-3,000,000	-6,500,000	-5,875,000	-6,375,000	-6,875,000	-9,875,000	-2,750,000	-1,250,000	-750,000	-1,750,000	-2,250,000
income taxes																								70,000	1,727,000				284,000	360,000	1,745,000	1,933,000	1,207,000	576,000	513,000	-401,000	755,000	2,435,000	653,000	1,311,000	2,406,000	408,000	1,177,000
interest																								171,000	217,000				456,000	479,000	470,000	296,000	292,000	285,000	248,000			19,000		45,000
prepaid expenses and other current assets																										1,713,000	-3,310,000
cash and cash equivalents at the beginning of the year
cash and cash equivalents at the end of the year
cash and cash equivalents at the beginning of the period																											0
cash and cash equivalents at the end of the period																											104,000
amortization of debt issuance costs																													27,000	27,000	28,000
gain on sale of assets
deferred income taxes																														-1,627,000	-1,221,000	0	138,000	-935,000	241,000
impairment loss on goodwill																														0
change in assets and liabilities, net of effects of acquisitions and dispositions
cash flow from financing activities:
cash paid during the year for:
change in assets and liabilities, net of effects of acquisitions
net decrease in cash and cash equivalents																																	-1,058,000
gain on dispositions
proceeds from disposition
purchase and retirement of common stock
repayment of employee loans for stock options																																				-68,000	0	92,000
loss on disposition of assets
proceeds from dispositions
net cash flows from operating activities																																					2,774,000	2,805,000		3,525,000	1,514,000	3,412,000
employee loans issued for the exercise of stock options																																								11,000
change in assets and liabilities, net of acquisitions
impairment of intangible asset
cash paid for interest																																													57,000	54,000	50,000
employee loans issued for exercise of stock options
stock based compensation																																								459,000	289,000	149,000		157,000	96,000	96,000	96,000	125,000	96,000	66,000	70,000	78,000	65,000	69,000	66,000	68,000	69,000	73,000
accrued liabilities																																										210,000
acquisition of net assets of a business
purchases of stock for treasury
repayment of employee loans related to the exercise of stock options																																								0
contingent consideration as part of the acquisition of net assets of a business																																								0
gain on loan settlement
business acquisitions and intangibles
capital expenditures
proceeds from debt																																										11,000,000
treasury stock purchases
proceeds from stock options exercised																																										312,000	294,000	7,000	34,000	478,000		61,000	47,000	29,000		4,000	81,000	4,000		76,000	40,000	48,000
impairment of intangible
accounts payable, trade
net cash (used) by investing activities
net cash (used) provided by financing activities																																																	-635,000	3,864,000
prepaid expenses
capital expenditures, building
change in assets and liabilities-
increase in accounts receivable																																													-137,000	498,000		96,000	19,000	537,000		116,000	-160,000	818,000				307,000
increase in inventories																																													385,000	337,000
increase in prepaid expenses																																													36,000	101,000	-71,000	-23,000	70,000	284,000		-37,000	3,000	194,000	-101,000	-35,000	-62,000	299,000
increase in accounts payable																																														55,000										-125,000	33,000	104,000
increase in accrued liabilities																																																992,000	-266,000	366,000
acquisition of product lines and company
deposits
capital expenditures, net of retirements
bank borrowing
debt payments
net cash (used) in investing activities
bank borrowing, net of debt payments
allowance for bad debt
change in assets and liabilities
increase in accounts payable, trade
increase in accrued liabilities and taxes payable
capital expenditures other, net of retirements
payments on long-term debt
repayment of sgm shareholder loans
tax benefit of nonqualified stock options
net proceeds from stock option exercises
treasury stock repurchases
supplemental disclosures of cash flow information:
bank borrowing, net of retirements
net cash (used) in provided by financing activities
acquisition of company
deposit
borrowing, net of retirements																																																	-250,000	4,193,000
supplemental disclosure of non-cash activity:
net cash (used) provided by operating activities																																																			1,098,000	1,778,000	1,072,000	2,032,000
product line acquired
net cash (used) provided by investing activities
net proceeds from issuance of stock
deposit on manufacturing equipment
net cash used by investing activities
common stock repurchases
net cash used by financing activities
benefit from inventory reserve
short-term investments redeemed
purchase of business
tax benefit of nonqualified stock options exercised
supplemental disclosures of non-cash investing and financing activities:
during the fiscal year 2007 the company acquired raven biological laboratories

We provide you with 20 years of cash flow statements for Mesa Laboratories stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Mesa Laboratories stock. Explore the full financial landscape of Mesa Laboratories stock with our expertly curated income statements.

The information provided in this report about Mesa Laboratories stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.